Janux Therapeutics, Inc.
JANX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $10.0M | $10.6M | −5.6% |
| Operating income | −$158M | −$98.8M | −59.5% |
| Net income | −$114M | −$69.0M | −64.7% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $9.30M | $10.0M | −7.0% |
| Operating income | −$31.3M | −$35.3M | +11.3% |
| Net income | −$21.6M | −$24.3M | +11.1% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Janux Therapeutics's revenue in FY2025?
- $10.0M in FY2025 (Fiscal year ended Dec 31, 2025), −5.6% vs $10.6M a year earlier, per its 10-K filed Feb 2026.
- Was Janux Therapeutics profitable in FY2025?
- No: net income was −$114M and operating income −$158M in FY2025.
- What was Janux Therapeutics's revenue in Q3 2026?
- $9.30M (−7.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.